Recombinant Human TRAIL R1/DR4/TNFRSF10A Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01256P-100UG

Human TRAIL R1 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human TRAIL R1/DR4/TNFRSF10A Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01256P-100UG
Collections: All products, High-quality recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human TRAIL R1/DR4/TNFRSF10A Protein is expressed from HEK293 with hFc tag at the C-Terminus.It contains Pro34-Asn239. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | O00220 |
Target Symbol | TRAIL R1/DR4/TNFRSF10A |
Synonyms | DR4; CD261; TNFRSF10A; TRAIL-R; APO2; TRAIL R1; MGC9365 |
Species | Human |
Expression System | HEK293 |
Tag | C-hFc |
Expression Range | Pro34-Asn239 |
Mol. Weight | The protein has a predicted MW of 48.8 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Human TRAIL, No Tag at 2ug/ml (100ul/well) on the plate. Dose response curve for Human TRAIL R1, hFc Tag with the EC50 of 25.4ng/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptosis selectively via its interaction with the death receptors TRAILR1/DR4 and TRAILR2/DR5 in a wide range of cancers, while sparing normal cells. Despite its tremendous potential for cancer therapeutics, the translation of TRAIL into the clinic has been confounded by TRAIL-resistant cancer populations. |